18-Nov-2026 08:17:32
LUPINGeneral news
NOMURA ON LUPIN ; BUY | TARGET ₹2,780
• Current valuations largely price in the expected near-term decline in US sales. • Cyclical weakness presents a favourable risk-reward opportunity over the next 1–2 years. • Expects sustained above-market growth in domestic formulations, driven by strong performance in chronic therapies. • Strong balance sheet provides opportunities for strategic tuck-in acquisitions to support future growth.
LUPIN LIMITED